GlassScriptPhysician profile
Phillip J Cozzi
NPI 1205887353
$703.62
in general payments reported to CMS, 2019-2025
11 companies · $94.31 in 2025
The $94.31 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.14 · 2021: $21.06 · 2022: $225 · 2023: $138 · 2024: $210 · 2025: $94.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.98 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $158.89 | 2023-2025 | Arexvy, Nucala, Shingrix |
| Pulmonx Corporation | $47.54 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Inari Medical, INC. | $44.48 | 2022 | |
| Viatris Specialty LLC | $42.39 | 2025 | Yupelri |
| Mylan Specialty L.P. | $39.47 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $37.04 | 2024 | Fasenra |
| Baxter Healthcare | $29.34 | 2022 | |
| United Therapeutics Corporation | $21.06 | 2021 | |
| Amgen INC. | $18.78 | 2024 | Prolia, Evenity |
| Csl Behring | $18.65 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Cozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.